RBC Capital Upgrades Neumora Therapeutics to Outperform
RBC Capital raises Neumora Therapeutics to Outperform, citing new growth opportunities beyond neurology and promising early data in multiple markets.
/ 911 items
#Healthcare↓
Biotech Meets Bitcoin: Apimeds and MindWave Merge with $100M Backing
Apimeds Pharmaceuticals merges with MindWave Innovations, combining pain management biotech with AI-driven Bitcoin treasury solutions, backed by $100 million funding.
Galecto Gains Momentum with New Drug Class and Strong Funding
Guggenheim initiates coverage on Galecto with a Buy rating and $32 target, citing strong potential for its newly acquired drug DMR-001 and solid funding through 2029.
FDA Fast-Tracks New Blood Cancer Treatment CLN-049 for AML
Cullinan Therapeutics (CGEM) receives FDA Fast Track designation for CLN-049, a novel therapy showing promising results in treating relapsed acute myeloid leukemia patients.
Q32 Bio Sells Drug Asset to Akebia Therapeutics
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront plus milestone payments up to $592M, extending cash runway to mid-2027 while focusing on alopecia treatment.
IDEAYA Gets FDA Green Light for Groundbreaking Cancer Treatment
IDEAYA Biosciences receives FDA clearance for IDE034, a first-in-class dual-target cancer therapy aimed at lung, colorectal, and head and neck tumors.